作者: Isabella P Godói , André S Santos , Edna A Reis , Livia LP Lemos , Cristina MR Brandão
关键词: Dengue virus 、 Environmental health 、 Global health 、 Dengue vaccine 、 Population 、 Dengue fever 、 Willingness to pay 、 Inclusion (education) 、 Public health 、 Medicine
摘要: Introduction and Objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that will potentially be paid via public system, information need regarding consumers' willingness to pay country as well discussions related possible inclusion of this into system. This objective research. Methods: We conducted cross-sectional study residents Greater Belo Horizonte, Minas Gerais, about their CYD-TDV vaccine. Results: 507 individuals were interviewed. These mostly female (62.4%) had completed high school (62.17%), working (74.4%), private insurance (64.5%) did not have (67.4%). The maximum median value US$33.61 (120.00BRL) complete schedule US$11.20 (40.00BRL) per dose. At price determined Brazil's regulatory chamber pharmaceutical products market commercialization Dengvaxia® three doses, only 17% population expressed Conclusion: Brazil currently one largest markets established key issue. believe manufacturer should asses possibility lower prices reach larger audience among Brazilian population.